A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs ABTL 0812 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Ability Pharmaceuticals
- 27 Sep 2018 Planned number of patients changed from 46 to 110.
- 27 Sep 2018 Planned End Date changed from 2 Sep 2020 to 30 Mar 2023.
- 27 Sep 2018 Planned primary completion date changed from 1 Sep 2020 to 30 Mar 2022.